Orphazyme A/S is a biotechnology business based in the US. Orphazyme A/S shares (ORPH) are listed on the NASDAQ and all prices are listed in US Dollars. Orphazyme A/S employs 180 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Orphazyme A/S
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ORPH – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Orphazyme A/S stock price (NASDAQ: ORPH)Use our graph to track the performance of ORPH stocks over time.
Orphazyme A/S shares at a glance
|Latest market close||$4.02|
|52-week range||$3.78 - $23.90|
|50-day moving average||$4.51|
|200-day moving average||$6.39|
|Wall St. target price||$1.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.98|
Buy Orphazyme A/S shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Orphazyme A/S stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Orphazyme A/S price performance over time
|1 week (2021-10-13)||-18.13%|
|1 month (2021-09-20)||-7.37%|
|3 months (2021-07-20)||-24.44%|
|6 months (2021-04-20)||-54.42%|
|1 year (2020-10-20)||-62.39%|
|2 years (2019-10-16)||N/A|
|3 years (2018-10-16)||N/A|
|5 years (2016-10-16)||N/A|
Orphazyme A/S financials
|Revenue TTM||$13.2 million|
|Gross profit TTM||$0|
|Return on assets TTM||-88.16%|
|Return on equity TTM||-251.34%|
|Market capitalisation||$153.3 million|
TTM: trailing 12 months
Shorting Orphazyme A/S shares
There are currently 302,519 Orphazyme A/S shares held short by investors – that's known as Orphazyme A/S's "short interest". This figure is 0.7% up from 300,548 last month.
There are a few different ways that this level of interest in shorting Orphazyme A/S shares can be evaluated.
Orphazyme A/S's "short interest ratio" (SIR)
Orphazyme A/S's "short interest ratio" (SIR) is the quantity of Orphazyme A/S shares currently shorted divided by the average quantity of Orphazyme A/S shares traded daily (recently around 1.1 million). Orphazyme A/S's SIR currently stands at 0.28. In other words for every 100,000 Orphazyme A/S shares traded daily on the market, roughly 280 shares are currently held short.
To gain some more context, you can compare Orphazyme A/S's short interest ratio against those of similar companies.
However Orphazyme A/S's short interest can also be evaluated against the total number of Orphazyme A/S shares, or, against the total number of tradable Orphazyme A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orphazyme A/S's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Orphazyme A/S shares in existence, roughly 10 shares are currently held short) or 0.0107% of the tradable shares (for every 100,000 tradable Orphazyme A/S shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Orphazyme A/S.
Find out more about how you can short Orphazyme A/S stock.
Orphazyme A/S share dividends
We're not expecting Orphazyme A/S to pay a dividend over the next 12 months.
Orphazyme A/S share price volatility
Over the last 12 months, Orphazyme A/S's shares have ranged in value from as little as $3.78 up to $23.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orphazyme A/S's is 0.7039. This would suggest that Orphazyme A/S's shares are less volatile than average (for this exchange).
To put Orphazyme A/S's beta into context you can compare it against those of similar companies.
Orphazyme A/S overview
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. .
Orphazyme A/S in the news
44 Biggest Movers From Yesterday
Orphazyme files to sell $75M of ordinary shares
TRADING UPDATES: ITM eyes fundraise; Marshall Motor buys Motorline
Frequently asked questionsWhat percentage of Orphazyme A/S is owned by institutions?
Currently 2.251% of Orphazyme A/S shares are held by institutions. How many people work for Orphazyme A/S?
Latest data suggests 180 work at Orphazyme A/S. When does the fiscal year end for Orphazyme A/S?
Orphazyme A/S's fiscal year ends in December. Where is Orphazyme A/S based?
Orphazyme A/S's address is: Ole MaalOees Vej 3, Copenhagen, Denmark, 2200 What is Orphazyme A/S's ISIN number?
Orphazyme A/S's international securities identification number is: US6873051022 What is Orphazyme A/S's CUSIP number?
Orphazyme A/S's Committee on Uniform Securities Identification Procedures number is: 687303107
More guides on Finder
How to buy Aura Biosciences (AURA) stock when it goes public
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
How to buy Claros Mortgage Trust (CMTG) stock when it goes public
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
How to buy Evotec SE (EVO) stock when it goes public
Everything we know about the Evotec SE IPO, plus information on how to buy in.
How to buy Delimobil Holding SA (DMOB) stock when it goes public
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
How to buy Blue Water Vaccines (BWV) stock when it goes public
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
How to buy Sonendo (SONX) stock when it goes public
Everything we know about the Sonendo IPO, plus information on how to buy in.
How to buy FlexEnergy Green Solutions (FLXE) stock when it goes public
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
How to buy Stran & Company (STRN) stock when it goes public
Everything we know about the Stran & Company IPO, plus information on how to buy in.
How to buy Kidpik Corp (PIK) stock when it goes public
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
How to buy Nuvectis Pharma (NVCT) stock when it goes public
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
Ask an Expert